Harvard Bioscience, Inc. (HBIO) P/E Ratio History
Deep ValueTrading at -0.5x · 0th percentile of 5-year range · Significant discount to historical valuation · Data 2002–2015
Loading P/E history...
P/E Ratio Analysis
As of June 28, 2026, Harvard Bioscience, Inc. (HBIO) trades at a price-to-earnings ratio of -0.5x, with a stock price of $6.04 and trailing twelve-month earnings per share of $-2.19.
The current P/E is 100% below its 5-year average of 113.9x. Over the past five years, HBIO's P/E has ranged from a low of 4.2x to a high of 855.9x, placing the current valuation at the 0th percentile of its historical range.
Compared to the Healthcare sector median P/E of 23.0x, HBIO trades at a 102% discount to its sector peers. The sector includes 231 companies with P/E ratios ranging from 0.0x to 191.4x.
Relative to the broader market, HBIO trades at a notable discount to the S&P 500 median P/E of 25.3x. Investors should consider the company's growth prospects, competitive position, and earnings quality when evaluating whether the current valuation is justified.
For a comprehensive intrinsic value estimate using discounted cash flow analysis, see our HBIO DCF Valuation Calculator →
Note: P/E ratio is just one valuation metric. It does not account for balance sheet strength, cash flow quality, or growth sustainability. Always conduct comprehensive due diligence before making investment decisions.
HBIO Cross-Benchmark Valuation
How does the current P/E compare to sector peers and the broader market?
HBIO P/E vs Peers
Diagnostics and life science tools peers sorted by market cap
| Company | Market Cap | P/E Ratio | PEG Ratio | EPS Growth (1Y) |
|---|---|---|---|---|
| $1B | 20.8Lowest | 0.68Best | +8% | |
| $566M | 84.6 | 6.23 | +436%Best | |
| $2B | 38.0 | 1.96 | +31% | |
| $24B | 34.8 | 6.72 | +0% | |
| $11B | 154.3 | - | -56% | |
| $191B | 28.9 | 13.69 | +7% |
Lower P/E can signal a discount or weaker growth expectations; PEG adds growth context.
HBIO Historical P/E Data (2002–2015)
Quarterly P/E ratios calculated from closing price and TTM EPS
| Quarter | Period End | Price | TTM EPS | P/E Ratio | vs Avg |
|---|---|---|---|---|---|
| FY2015 Q1 | - | $58.20 | $0.07 | 855.9x | +790% |
| FY2014 Q4 | Dec 31 2014 | $56.70 | $0.69 | 81.7x | -15% |
| FY2014 Q3 | - | $40.90 | $0.47 | 87.8x | -9% |
| FY2013 Q3 | Sep 30 2013 | $40.20 | $0.05 | 820.4x | +753% |
| FY2013 Q2 | Jun 30 2013 | $35.90 | $0.33 | 110.5x | +15% |
| FY2013 Q1 | Mar 31 2013 | $43.10 | $0.68 | 63.0x | -35% |
| FY2012 Q4 | Dec 31 2012 | $33.50 | $0.85 | 39.2x | -59% |
| FY2012 Q3 | Sep 30 2012 | $32.30 | $0.75 | 42.8x | -55% |
| FY2012 Q2 | Jun 30 2012 | $28.80 | $0.81 | 35.6x | -63% |
| FY2012 Q1 | Mar 31 2012 | $29.90 | $1.01 | 29.6x | -69% |
| FY2011 Q4 | Dec 31 2011 | $29.60 | $1.41 | 21.0x | -78% |
| FY2011 Q3 | Sep 30 2011 | $32.20 | $1.91 | 16.9x | -82% |
| FY2011 Q2 | - | $40.70 | $6.30 | 6.5x | -93% |
| FY2011 Q1 | - | $43.40 | $6.40 | 6.8x | -93% |
| FY2010 Q4 | Dec 31 2010 | $31.20 | $6.50 | 4.8x | -95% |
| FY2010 Q3 | - | $29.00 | $6.90 | 4.2x | -96% |
| FY2010 Q2 | Jun 30 2010 | $27.20 | $2.90 | 9.4x | -90% |
| FY2010 Q1 | Mar 31 2010 | $29.60 | $2.40 | 12.3x | -87% |
| FY2009 Q4 | - | $27.30 | $2.30 | 11.9x | -88% |
| FY2009 Q3 | Sep 30 2009 | $28.90 | $1.70 | 17.0x | -82% |
| FY2009 Q2 | - | $30.20 | $1.70 | 17.8x | -82% |
| FY2009 Q1 | - | $22.80 | $0.90 | 25.3x | -74% |
| FY2008 Q4 | Dec 31 2008 | $20.20 | $0.50 | 40.2x | -58% |
| FY2005 Q1 | - | $29.70 | $0.80 | 37.1x | -61% |
| FY2004 Q4 | Dec 31 2004 | $35.40 | $0.68 | 51.8x | -46% |
| FY2004 Q3 | - | $33.20 | $0.98 | 33.8x | -65% |
| FY2004 Q2 | Jun 30 2004 | $34.20 | $0.98 | 34.8x | -64% |
| FY2004 Q1 | Mar 31 2004 | $70.80 | $1.08 | 65.4x | -32% |
| FY2003 Q4 | Dec 31 2003 | $68.00 | $1.36 | 50.1x | -48% |
| FY2003 Q3 | - | $56.70 | $0.42 | 133.4x | +39% |
| FY2003 Q2 | Jun 30 2003 | $29.00 | $0.09 | 308.5x | +221% |
| FY2003 Q1 | Mar 31 2003 | $28.60 | $0.29 | 97.3x | +1% |
| FY2002 Q4 | - | $25.20 | $0.32 | 78.3x | -19% |
| FY2002 Q3 | Sep 30 2002 | $23.10 | $0.49 | 47.3x | -51% |
| FY2002 Q2 | Jun 30 2002 | $42.70 | $0.62 | 69.0x | -28% |
Average P/E for displayed period: 96.2x
Intrinsic Valuation
DCF models, multiple analysis, and analyst estimates.
Historical Returns
24+ years return with dividends reinvested.
DCA Calculator
See how regular investing compounds over time.
Peer Comparison
Compare growth, multiples, and margins vs sector.
HBIO — Frequently Asked Questions
Quick answers to the most common questions about buying HBIO stock.
What is HBIO's P/E ratio?
Harvard Bioscience, Inc. (HBIO) trailing twelve-month P/E ratio is -0.5x, based on TTM diluted EPS of $-2.19. The 5-year average P/E is 113.9x and the historical range spans 4.2x to 855.9x.
Is HBIO stock overvalued or undervalued?
HBIO trades at -0.5x P/E, below its 5-year average of 113.9x. At the 0th percentile of its historical range (4.2x–855.9x), the stock is priced at a discount to its own history.
Is HBIO stock expensive?
No, HBIO is not expensive on a historical basis. The current P/E of -0.5x is below the 5-year average of 113.9x and sits at the 0th percentile of its valuation range.
What is HBIO's historical P/E range?
Over the past 5 years, HBIO's P/E ratio has ranged from 4.2x to 855.9x, with a median of 29.6x and an average of 113.9x. The current P/E of -0.5x places the stock at the 0th percentile of this range. Full historical data spans 2002–2015.
How does HBIO's P/E compare to the S&P 500?
HBIO trades at -0.5x P/E versus the S&P 500 median of 25.3x. The 102% discount to the market suggests lower growth expectations or perceived higher risk.
How does HBIO's valuation compare to Healthcare peers?
Harvard Bioscience, Inc. P/E of -0.5x compares to the Healthcare sector median of 23.0x. The discount suggests lower growth expectations, weaker margins, or higher perceived risk relative to peers. See the peer comparison table on this page for ticker-by-ticker P/E and PEG.
What is HBIO's PEG ratio?
HBIO PEG ratio is N/A, based on a P/E of -0.5x and EPS growth of -357.1%. PEG normalises P/E by growth and helps compare stocks with different earnings trajectories.
What is HBIO's earnings yield?
HBIO earnings yield is N/A, the inverse of its -0.5x P/E ratio. Earnings yield represents the percentage of each dollar invested that the company earns. It can be compared directly to bond yields to assess relative attractiveness of stocks versus fixed income.